BioSpace News Archive

Rho’s Meagan Vaughn was recently honored at the Cystic Fibrosis (CF) Foundation’s annual “Brewer’s Ball Celebrating Triangle’s Finest” event.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, today announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 study of NurOwn® in patients with progressive multiple sclerosis (MS).

Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, today announced that it has commenced its previously announced rights offering of $45,000,000 of its common stock.

IntraBio Inc., a late-stage biopharmaceutical company developing novel therapies for rare (“orphan”) and common neurodegenerative diseases, announced that the European Commission has granted Orphan Medicinal Drug Designation for its lead compound series (IB1000s) for the treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease), a rare lysosomal storage disorder that is characterized by rapid, progressive neurodegeneration and premature death.

Indivior PLC (LON: INDV) today announced that PERSERISTM(risperidone) for extended-release injectable suspension is now available in the United States. PERSERIS is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults.

KidneyCure Ltd, a biotech company developing a novel cell-therapy technology for treating advanced chronic kidney disease, is expanding its circle of investors. The comapny has completed a round of financing from Aurum Ventures, a venture capital firm, and Direct Insurance Financial Investments.

According to the latest research by the company, the global pharma-grade synthetic camphor market size is anticipated to be valued at US$ 532.0 Mn, by 2028 end.

A new clinical study conducted by Wake Forest School of Medicine shows that use of a new non-invasive technology from the creators of Cereset not only reduces symptoms of military-related traumatic stress but also improves brain function

Bionic Vision Technologies Pty Ltd (BVT) today announced medical researchers had successfully restored a sense of vision in four blind people with its bionic eye as part of a clinical trial in Melbourne.

Mazor Robotics Ltd. today announced that at a Special General Meeting of Shareholders held earlier today, Mazor Robotics shareholders approved the previously announced definitive merger agreement with wholly-owned subsidiaries of Medtronic plc (NYSE: MDT).